(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the appointment of Sheng-FU Hsiao as Chief Technology Officer (CTO), effective March 1, 2026. This appointment aligns with the Company’s 2026 management strategy, "Sophistication of Management Structure through AI and DX," and strengthens its leadership team to accelerate technological transformation.
SBC Medical is transitioning from a traditional labor-intensive management model to an AI-driven infrastructure to address structural challenges in the medical industry, such as productivity, quality, and transparency. The Company aims to establish a next-generation operating system―an "Automated Management Infrastructure" that optimizes everything from decision support to operational execution with high reproducibility and scalability.
To lead this technological shift, SBC Medical has welcomed Mr. Hsiao, who brings a proven track record of spearheading AI-specialized organizations and establishing IT governance for pre-IPO companies. In his previous roles, Mr. Hsiao successfully automated large-scale operations, including the implementation of AI call centers that reduced labor requirements by approximately 31% (equivalent to approximately 50 personnel) and improved response times by 30%. He also led the modernization of 20-year-old legacy systems into flexible microservices architectures. At SBC Medical, Mr. Hsiao will oversee the modernization of existing core systems and transform the Group’s vast clinical, customer, and management data into a strategic AI asset, while ensuring the highest standards of security, ethics, and data governance.
Key Initiatives for AI Transformation
Mr. Hsiao will work alongside Vice President Yuya Yoshida to lead the Group’s AI strategy. By integrating the vision of "SBC AI Lab" ―the in-house development organization led by Mr. Yoshida―with Mr. Hsiao’s technical execution capabilities, the Company will redesign its management "OS" beyond simple operational efficiency.
1. Autonomous Operations and Advanced Management
Implementation of AI-driven infrastructure to optimize all processes, from back-office tasks to patient booking flows. This scalable model aims to suppress fixed-cost ratios during business expansion.
Notes:
*1: Figures as of the end of December 2025, encompassing SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH, JUN CLINIC, and OrangeTwist.
*2: Figures as of the end of December 2025, encompassing SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH, and JUN CLINIC (with certain exceptions). These figures exclude free consultations. Unique patient counts and repeat rates for AHH and JUN CLINIC are estimated based on the ratio to the annual patient counts of the SBC brand, Rize Clinic, and Gorilla Clinic.
2.Customer Experience (UX) Innovation
Development of an "AI Concierge" providing 24/7 support and "AI Mirrors" for objective data visualization of treatment results, enhancing medical transparency.
3. Global Expansion of Medical OS
Deploying the AI-native management platform proven in Japan to global markets, including the U.S. and Southeast Asia, to rapidly replicate high-quality clinic operations.
About Sheng-FU Hsiao
After graduating from National United University in Taiwan, Mr. Hsiao studied at Curtin University in Australia. Following a career in trade management in China, he moved to Japan in 2008. He has served as CTO for over eight years across various organizations, driving growth through restructuring and advanced development. Most recently, he served as Executive Officer and CTO at an AI-specialized firm. He is fluent in Japanese, English, Mandarin, and Taiwanese.
Comment from Sheng-FU Hsiao
"I am confident that implementing the 'Automated Management Infrastructure' envisioned by SBC Medical will cause a paradigm shift in the medical industry. Working with Mr. Yoshida, I am committed to converting our massive data assets into value, delivering the highest standard of medical experience to customers worldwide, and creating an environment where medical professionals can focus on highly specialized tasks."
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com/ For more insights and updates from SBC Holdings, follow us on LinkedIn
Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260302064873/en/
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Head of Public Relations; E-mail: pr@sbc.or.jp
ICR LLC (US Time)
Bill Zima / Managing Partner; E-mail: bill.zima@icrinc.com
